Table 1. Patient characteristics.
| Characteristic | PD-L1 (n=145) | B3GNT3 (n=145) | |||||
|---|---|---|---|---|---|---|---|
| Positive (>1%) | Negative (<1%) | P value | Positive | Negative | P value | ||
| Age, years, median [range] | 61 [40–75] | 60 [28–84] | 0.345a | 60 [28–84] | 62 [45–75] | 0.279a | |
| Male:female | 22:17 | 17:60 | 0.164b | 56:67 | 12:10 | 0.435b | |
| Smoking | 0.592b | 0.064b | |||||
| Yes | 10 (25.6%) | 32 (30.2%) | 32 (26.0%) | 10 (45.5%) | |||
| No | 29 (74.4%) | 74 (69.8%) | 91 (74.0%) | 12 (54.5%) | |||
| Location | 0.869b | 0.398b | |||||
| Left upper lobe | 12 (30.8%) | 40 (37.7%) | 41 (33.3%) | 11 (50.0%) | |||
| Left lower lobe | 6 (15.4%) | 11 (10.4%) | 14 (11.4%) | 3 (13.6%) | |||
| Right upper lobe | 9 (23.1%) | 25 (23.6%) | 30 (24.4%) | 4 (18.2%) | |||
| Right middle lobe | 4 (10.3%) | 8 (7.5%) | 12 (9.8%) | 0 (0.0%) | |||
| Right lower lobe | 8 (20.5%) | 22 (20.8%) | 26 (21.1%) | 4 (18.2%) | |||
| Clinical T stage (AJCC 8th ed.) | 0.086c | 0.104c | |||||
| pT1a | 1 (2.6%) | 3 (2.8%) | 2 (1.6%) | 2 (9.1%) | |||
| pT1b | 11 (28.2%) | 14 (13.2%) | 23 (18.7%) | 2 (9.1%) | |||
| pT1c | 7 (17.9%) | 16 (15.1%) | 22 (17.9%) | 1 (4.5%) | |||
| pT2a | 12 (30.8%) | 59 (55.7%) | 59 (48.0%) | 12 (54.5%) | |||
| pT2b | 4 (10.3%) | 7 (6.6%) | 9 (7.3%) | 2 (9.1%) | |||
| pT3 | 4 (10.3%) | 5 (4.7%) | 7 (5.7%) | 2 (9.1%) | |||
| pT4 | 0 (0.0%) | 2 (1.9%) | 1 (0.8%) | 1 (4.5%) | |||
| Clinical N stage (AJCC 8th ed.) | 0.990b | 0.946b | |||||
| pN0 | 29 (74.4%) | 80 (75.5%) | 93 (75.6%) | 16 (72.7%) | |||
| pN1 | 3 (7.7%) | 8 (7.5%) | 9 (7.3%) | 2 (9.1%) | |||
| pN2 | 7 (17.9%) | 18 (17.0%) | 21 (17.1%) | 4 (18.2%) | |||
| TNM stage (AJCC 8th ed.) | 0.389c | 0.123c | |||||
| IA1 | 1 (2.6%) | 3 (2.8%) | 2 (1.6%) | 2 (9.1%) | |||
| IA2 | 11 (28.2%) | 14 (13.2%) | 23 (18.7%) | 2 (9.1%) | |||
| IA3 | 6 (15.4%) | 15 (14.2%) | 20 (16.3%) | 1 (4.5%) | |||
| IB | 8 (20.5%) | 42 (39.6%) | 42 (34.1%) | 8 (36.4%) | |||
| IIA | 1 (2.6%) | 3 (2.8%) | 2 (1.6%) | 2 (9.1%) | |||
| IIB | 4 (10.3%) | 8 (7.5%) | 11 (8.9%) | 1 (4.5%) | |||
| IIIA | 7 (17.9%) | 17 (16.0%) | 19 (15.4%) | 5 (22.7%) | |||
| IIIB | 1 (2.6%) | 3 (2.8%) | 3 (2.4%) | 1 (4.5%) | |||
| IVA | 0 (0.0%) | 1 (0.9%) | 1 (0.8%) | 0 (0.0%) | |||
| EGFR mutation | 0.615b | 0.039b | |||||
| Yes | 24 (61.5%) | 70 (66.0%) | 84 (68.3%) | 10 (45.5%) | |||
| No | 15 (38.5%) | 36 (34.0%) | 39 (31.7%) | 12 (54.5%) | |||
a, Wilcoxon test; b, Pearson’s chi-Square T test; c, Fisher’s exact test.